IQVIA rapport. Make a deal or not… the emerging pharmacy’s dilemma

The emerging pharmaceutical and biotech industry is thriving. Between 2006 and 2015, 105 companies – the majority of which were in the U.S. – launched a product for the first time. And, over 60 percent of those products were originally discovered in universities and small biotech companies.

Lees hier het IQVIA rapport make a deal or not… the emerging pharmacy’s dilemma

All such pre-commercial companies must make a fundamental decision at some point in the drug development process: is it more advantageous to take the product to market on our own or to partner with an established large pharmaceutical company? This decision is typically made as developers approach the end of Phase II clinical trials, but can take place at any time—even after the drug has launched.